The population in SELECT was different that STEP-1 and SUMOUNT 1, with 90.1% of patients on lipid-lowering therapy and a much lower baseline LDL-C of 78 mg/dL compared to 111 mg/dL and 110 mg/dL in STEP-1 and SURMOUNT 1 respectively [33, 35, 48]
The Breakthrough: Tirzepatide and Semaglutide Recent advancements in obesity treatment have brought two powerful medications to the forefront: semaglutide (brand names: Wegovy, Ozempic ) and tirzepatide (brand names: Zepbound, Mounjaro )
Further, inclusion of the safety measures in the first study, even though they were burdensome, helped validate the safety of these medications in individuals with an opioid use disorder
HDAC assay In vitro deacylation assays were performed as described previously 20 with some modifications
The only difference in CarbOx was over 24-hour, where placebo had higher CarbOx than SAR425899, likely due to the shift to fat oxidation in the SAR425899 group (p=0.006